Every 8-K that Athira Pharma, Inc. (ATHA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ATHA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATHA filings page.
LeonaBio, Inc. reported first quarter 2026 results and highlighted progress in its oncology and neurodegeneration pipeline. The company is running the Phase 3 ELAINE‑3 trial of lasofoxifene in ER‑positive, HER2‑negative, ESR1‑mutated metastatic breast cancer, plans to increase enrollment to up to 600 patients, expects to complete enrollment in 4Q 2026 and to report topline data in the second half of 2027.
ATH‑1105, an oral, brain‑penetrant candidate for ALS, showed favorable safety, pharmacokinetics and CNS penetration in a Phase 1 trial, and LeonaBio aims to start a Phase 2 proof‑of‑concept study in ALS patients in the second half of 2026. Cash, cash equivalents and investments were $67.7 million as of March 31, 2026, compared with $88.3 million as of December 31, 2025, reflecting higher operating spend.
Research and development expenses rose to $11.3 million for the quarter from $4.3 million a year earlier, mainly from the ELAINE‑3 trial, while general and administrative expenses increased to $6.9 million from $5.2 million. Net loss widened to $32.9 million, or $1.73 per share, from $9.1 million, or $2.34 per share, driven in part by a non‑cash $16.3 million change in fair value of a Sermonix pre‑funded warrant.
LeonaBio, Inc. filed a second amendment to an earlier report to align with SEC guidance treating its Sermonix transaction as an acquisition of a business. The company obtained a waiver from certain financial statement requirements in exchange for providing expanded qualitative and cash expenditure disclosures.
The amendment details historical unaudited cash spending on the ELAINE-3 Study, including about $14 million, $12 million and $5 million by Sermonix in 2023, 2024 and part of 2025, and approximately $11 million by LeonaBio from December 18 through December 31, 2025. LeonaBio now expects to spend about $45 million in 2026 and $30 million in 2027 as it broadens the study scope.
The company has increased the ELAINE-3 Study intensity, expanded the contract research organization’s responsibilities, and plans to raise the sample size from 500 to up to 600 participants. It currently expects to complete enrollment in the fourth quarter of 2026 and release topline data in the second half of 2027.
LeonaBio, Inc. reported full-year 2025 results and highlighted a major strategic shift toward oncology and neurodegeneration. For the year ended December 31, 2025, cash, cash equivalents and investments rose to $88.3 million from $51.3 million, helped by a $90 million private placement of common stock and warrants that could bring in up to an additional $146 million if fully exercised.
Research and development expenses increased to $85.6 million, mainly from $68.1 million of acquired in‑process R&D tied to the lasofoxifene license, while general and administrative expenses fell to $16.7 million. Net loss widened modestly to $105.6 million, or $24.70 per share, compared with $96.9 million, or $25.19 per share, in 2024.
The company acquired an exclusive global license (excluding Asia and certain Middle East countries) to late‑stage breast cancer drug candidate lasofoxifene and is running the Phase 3 ELAINE‑3 trial, expecting enrollment completion in 4Q 2026 and topline data in 2H 2027. Its ALS candidate ATH‑1105 showed favorable Phase 1 safety and CNS penetration, with a Phase 2 proof‑of‑concept study in ALS planned to start in the second half of 2026.
LeonaBio, Inc. reported results of a special stockholder meeting where several major equity actions were approved. Stockholders adopted a new 2026 Equity Incentive Plan allowing issuance of up to 5,700,000 shares, plus up to 1,300,000 additional shares recycled from certain expired or forfeited awards under the prior 2020 plan, and an annual increase tied to up to 5% of outstanding common stock and pre-funded warrants.
Stockholders also approved potential issuances of common stock upon exercise of a Sermonix pre-funded warrant for 5,502,402 shares and additional warrant exercises by Perceptive Advisors that could raise their beneficial ownership above 19.99%, consistent with Nasdaq Rules 5635(a)(2) and 5635(b). In a major capital structure change, authorized common stock increased from 90,000,000 to 400,000,000 shares and total authorized capital stock from 190,000,000 to 500,000,000 shares via a certificate of amendment filed on March 18, 2026.
Athira Pharma, Inc. has changed its corporate identity to LeonaBio, Inc. Effective January 9, 2026, the company adopted the new name and updated its certificate of incorporation and bylaws accordingly, without requiring stockholder approval and without changing stockholder rights.
The company will begin trading on the Nasdaq Capital Market under the new ticker symbol “LONA” at market open on January 12, 2026, with no CUSIP change or required action by stockholders. LeonaBio also launched a new corporate website at www.leonabio.com, which will host investor materials and governance documents.
Separately, the company entered into an amended and restated change in control and severance agreement with Chief Financial Officer Robert Renninger, providing specified cash severance, COBRA benefits and accelerated vesting of service-based equity upon certain terminations, and increased his annual base salary to $460,000, effective retroactively as of December 16, 2025.
Athira Pharma amended a recent report to add exhibit hyperlinks and detailed two major transactions that reshape its pipeline and funding. The company agreed to a $90 million PIPE private placement, issuing common stock, pre-funded warrants, and short-dated Series A and B warrants, with Cantor as placement agent. Net proceeds are earmarked for working capital, primarily to advance lasofoxifene and ATH-1105, and are expected to extend the company’s cash runway into 2028.
Athira also executed the Sermonix Transaction, licensing global (ex-Asia/Middle East) rights to lasofoxifene and entering a parallel license with Ligand. Upfront consideration includes about $34.9 million in equity to Sermonix, roughly $16.8 million of assumed third‑party obligations, monthly payments creditable against future milestones, and potential milestones up to $100 million plus royalties. Sermonix receives a pre-funded warrant for 5,502,402 shares, subject to stockholder approval mechanics and a capped cash redemption right. Athira updates its strategy to focus on late-stage lasofoxifene in ESR1‑mutated metastatic breast cancer and ATH‑1105 in ALS.
Athira Pharma is raising new capital and reshaping its pipeline around oncology and ALS. The company entered into a private placement with institutional investors to sell 5,356,547 common shares and pre-funded and common warrants linked to additional shares at a purchase price of $6.35–$6.349 per share or pre-funded warrant, for expected gross proceeds of about $90 million before fees. Certain investors, including Perceptive-related funds, are participating, and two large investors gain the right to designate Board members while two current directors are expected to resign within six months of closing.
Athira simultaneously signed licensing deals with Sermonix and Ligand for oral lasofoxifene outside Asia and parts of the Middle East, assuming the global Phase 3 ELAINE‑3 trial and related manufacturing and service contracts. Consideration includes approximately $34.9 million in equity via a 5,502,402‑share pre‑funded warrant, monthly payments, and up to $100 million in milestones to Sermonix plus milestone and royalty obligations to Ligand. As of September 30, 2025, Athira had $25.2 million in cash, cash equivalents and investments and now expects, with private placement proceeds, to fund development of lasofoxifene and ALS candidate ATH‑1105 into 2028.
Athira Pharma (ATHA) furnished an 8-K stating it issued a press release reporting financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company notes that information under Items 2.02 and 7.01, and Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. Athira also highlights its disclosure channels, including its website, investor site, and social media accounts on X (@athirapharma), LinkedIn, Instagram (@athirapharma), and Facebook.
Athira Pharma, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price listing rule. The company previously received a notice on October 16, 2024 that its common stock had closed below $1.00 per share for 30 consecutive business days, triggering a deficiency under Nasdaq’s minimum bid requirement.
Nasdaq has now informed Athira that the closing bid price of its common stock was at least $1.00 per share for ten consecutive business days as of October 2, 2025. As a result, Athira is again in compliance with the minimum bid rule and Nasdaq has closed the deficiency matter.
Athira Pharma, Inc. is implementing a 10-for-1 reverse stock split of its common stock, effective as of 5:00 p.m. Eastern Time on September 17, 2025. This means every ten existing shares will be combined into one share, while the par value per share remains $0.0001.
The company is also reducing its authorized common stock from 900,000,000 to 90,000,000 shares and total authorized capital stock from 1,000,000,000 to 190,000,000 shares. Athira’s common stock is expected to begin trading on a post-split basis on The Nasdaq Capital Market on September 18, 2025 under the symbol ATHA.
Fractional shares resulting from the reverse split will be settled in cash, and proportional adjustments will be made to outstanding options, restricted stock units, and equity plan reserves. Stockholders holding shares in book-entry or through brokers will have their holdings automatically adjusted without needing to take action.